INDIANOLA, Pa. MEDRAD has introduced the Certo MR Wireless Network, a revolutionary wireless network for magnetic resonance (MR) imaging. The new system provides greater flexibility by allowing MEDRAD wireless-enabled equipment to move freely both in the MRI suite and in the control room.

The first wireless-enabled MEDRAD product to operate on the Certo Network is the Veris MR Patient Monitor with the Veris remote display. Certo allows Veris to freely travel with the patient from the prep room to the scanner room and then to the recovery area, while maintaining full communication with the remote display on the network. Clinicians can focus less on equipment and more on patient care while efficiently managing patients through the scanner suite.

MEDRADs focus is to identify market needs and then create innovative products that deliver high customer value, said Gary Bucciarelli, senior vice president, magnetic resonance business unit. The MR marketplace is ready for a robust, reliable wireless network like Certo for the flexibility, ease-of-care, and increased throughput demanded of MR healthcare providers.


For over a decade, MEDRAD has delivered advanced technology to the MR suite and supported it with a robust global support organization. Other MEDRAD MR products include the Spectris Solaris EP Injection System, a wide array of Leading Image Coils, Continuum MR Infusion System, as well as the Veris MR Patient Monitor, winner of the Frost & Sullivan Customer Value Enhancement Award in 2005.

To learn more about the Certo MR Wireless Network, customers can contact their MEDRAD representative.

MEDRAD, INC. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRADs product offerings include a comprehensive line of vascular injection systems, magnetic resonance (MR) surface coils and patient care products, and equipment services. Total 2005 revenues were $411 million. MEDRAD is a 2003 recipient of the Malcolm Baldrige National Quality Award, the top honor a U.S. company can receive for quality and business excellence. The companys world headquarters is near Pittsburgh, Pennsylvania, in the United States.

MEDRAD is a U.S. affiliate of Schering AG, Germany (FSE:SCH; NYSE:SHR). It is planned that Schering AG will be renamed Bayer Schering Pharma Aktiengesellschaft. A corresponding resolution was passed at the Extraordinary General Meeting of Schering AG on September 13, 2006. Until the name change has been registered in the commercial register, the company will continue to operate under the name Schering AG. According to the resolution of the General Meeting, the Executive Board will not file an application for registration before December 1, 2006.

Back to HCB News

More Voices